Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pembrolizumab and Flutamide for Advanced Head and Neck Squamous Cell Carcinoma
NCT06694350Phase 2Not yet recruiting
- Sponsor
- Zhejiang Provincial People's Hospital
- Start
- Dec 2024
- Primary completion
- Dec 2027
- Modality
- Small Molecules
01
Overview
Phase 2, open-label, single-arm trial of flutamide in head and neck squamous cell carcinoma (HNSCC), sponsored by Zhejiang Provincial People's Hospital. Primary endpoint: Progression-Free Survival up to 4 years. Planned start Dec 2024; status: not yet recruiting.
02
Drugs
flutamide
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on NCT06694350.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06694350.